Introduction {#Sec1}
============

Thoracic endovascular aortic repair (TEVAR), which was introduced in 1998 as a less invasive treatment option for type B aortic dissection (AD), is now widely used in China^[@CR1]^. A meta-analysis by our group in 2009 on studies published from 2001 to 2007 including over 1300 patients documented that effectiveness of TEVAR for type B AD in mainland China compared favorably with that in Western countries (1999--2004)^[@CR2]^. To gain insight into temporal evolution of clinical outcomes, baseline characteristics and use of TEVAR among type B AD patients in mainland China, the present meta-analysis summarized multicenter data published in 2008--2015 and compared them to previous periods in China and Western countries.

Materials and Methods {#Sec2}
=====================

Data sources and study selection {#Sec3}
--------------------------------

"Aorta," "dissection" and "stent" were used as key words for a comprehensive search of both English- and Chinese-language literature and postgraduate theses in PubMed, Embase, CNKI (Chinese National Knowledge Infrastructure) and CQVIP databases. All Chinese studies on TEVAR published between January 2008 and October 2015 were identified for further analysis. Inclusion criteria were: (1) articles including patients with type B AD undergoing retrograde endovascular stent-graft placement into the descending thoracic aorta; and (2) a series of at least 5 patients with type B AD who underwent TEVAR. Exclusion criteria were: (1) reports on antegrade, surgical ("open") stent-graft placement through the aortic arch; (2) case reports; (3) reports on traumatic type B AD, iatrogenic injury, penetrating aortic ulcer or intramural hematoma; (4) reports on connective tissue disease (e.g., Marfan syndrome or Ehlers-Danlos syndrome); and (5) reports on other thoracic aortic pathologies (e.g., aneurysms).

Data extraction and statistical analysis {#Sec4}
----------------------------------------

Each article was analyzed using a standardized protocol with 35 predefined variables including clinical characteristics, procedural data, and in-hospital and long-term outcomes (Table [S1](#MOESM1){ref-type="media"}). The statistical outcomes and figures were generated using STATA 12 software (StataCorp, College Station, Texas, USA) and Prism 6.0 software (GraphPad Software, Inc, CA, USA). Unspecified information was classified as unavailable and was not used for meta-analysis.

Rates of events were calculated as number of events divided by number of treated patients with available data. A weighted average estimate was calculated by combining individual study results. Weight assigned to each individual study was proportional to its sample size.

Results are presented as proportion, median with range or mean with standard deviation, as appropriate. The distribution of cases by geographic area (Chinese province/autonomous regions/municipalities) and medical specialty performing TEVAR (cardiology; vascular surgery; cardiothoracic surgery; interventional radiology; and general surgery) was described, analyzed and compared with the results from the aforementioned meta-analysis on studies published between January 2001 to December 2007 (Chinese data 2001--2007)^[@CR2]^, as well as from the representative meta-analysis by Eggebrecht *et al*. of European and North American studies published between January 1999 and May 2004^[@CR3]^. Western, and 2001--2007 and 2008--2015 Chinese data were compared using 2-sided Student *t* test. Kaplan--Meier survival curves were used to estimate in-hospital/30-day and long-term death. Rates of in-hospital/30-day procedure-related death and long-term death of patients who underwent TEVAR were compared with that of non--procedure related death by using the log-rank test. A *p* \< 0.05 was considered statistically significant. Causes of in-hospital/30-day and long-term mortality were described.

Data availability {#Sec5}
-----------------

All relevant data are within the paper.

Definitions {#Sec6}
===========

Type B AD was classified based on the Stanford classification^[@CR4]^. Dissection was considered as an acute event if occurring within the first 14 days after symptom onset, and chronic if beyond 14 days. Complications were classified as either major when life-threatening or prompting major therapeutic interventions (e.g., access complications requiring surgical revision), or minor when not requiring further treatment (e.g., transient renal failure not requiring dialysis). Stent-graft implantation was based on indications described by Nienaber and colleagues^[@CR5]^, although some, such as distance between landing zone not \<1.5 cm, maximal aortic diameter \>5.5 cm, and no bilateral iliac tortuosity and stenosis, were not followed because of more positive attitude about TEVAR^[@CR6],[@CR7]^, accumulating experience and device improvement^[@CR8],[@CR9]^. For left subclavian artery (LSA) revascularization, use of surgical debranch or chimney technique was at operator's discretion before intentional LSA coverage. Technical details of TEVAR were as described by Nienaber and colleagues^[@CR5]^. Procedural success was defined as the technically successful deployment of the stent-graft at the intended target location. Any death that occurred suddenly or could not be related to other causes was defined as aortic rupture related death. Reintervention was defined as the need for any surgical conversion or additional endovascular stent-graft procedures. Procedure-related deaths refer to those related to endovascular stent placement (e.g., retrograde dissection, organ or peripheral artery malperfusion, or dissection rupture). Non--procedure-related deaths refer to those (e.g., myocardial infarction, cancer or multiple organ failure) unrelated to endovascular stent-graft placement.

Results {#Sec7}
=======

Study Selection {#Sec8}
---------------

After excluding 91 studies with non-relevant abstract and 54 studies with \<5 cases reported or traumatic dissection reports, 368 studies were selected for further full text review. Among the latter, 193 were excluded because of duplicate publications or overlapping data, and 175 studies were eventually selected for data extraction and analysis (supplemental references). A total of 11879 patients who underwent TEVAR were included in this meta-analysis (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Flowchart of article inclusion and exclusion.

Study and Patient Characteristics {#Sec9}
---------------------------------

An overview of study and patient characteristics is presented in Table [1](#Tab1){ref-type="table"}. A total of 173 hospitals and 176 departments were included in the meta-analysis. Among patients with pertinent information: average age (among 8,580 patients) was 53.9 years; 70.6% (among 7,677 patients) were male; 70.2% (among 4,890 patients) had acute dissection; 83.5% (among 6,693 patients) had hypertension; and 5.4% (among 3,402 patients) had diabetes.Table 1Overview of study and patient characteristics.Data available (n)No. of events or casesTotal No. of studies included175Total No. of hospitals included173Total No. of departments included176No. of patients with type B AD11879Average No. of patients with type B AD per study67\*36^\#^ (5--674)Patient age (y)858053.9\*Male sex76776184 (80.6 ± 0.5%)Acute dissection48903432 (70.2 ± 4.4%)Hypertension66935591 (83.5 ± 0.6%)Diabetes3402185 (5.4 ± 0.0%)\*Average, ^\#^Median, AD: aortic dissection.

Numbers of included studies, patients, hospitals and departments by geographic area are shown in Table [2](#Tab2){ref-type="table"}. Two municipalities and 4 provinces (Beijing, Shanghai, Zhejiang, Yunnan, Liaoning and Hunan) had over 100 patients per department. Among departments with published cases, the department of vascular surgery from Zhongshan Hospital in Shanghai had the largest number (443) of type B AD cases. Figure [2A](#Fig2){ref-type="fig"} shows TEVAR case prevalence by geographic region. Number of cases was categorized into 5 levels (green: \<50, brown: 50- \<100, blue: 100- \<500, yellow: 500- \<1000, and red: 1000--1500). Except for Tibet, all 22 provinces, 4 autonomous regions and 4 municipalities reported on TEVAR for type B AD. Two municipalities and 2 provinces (Shanghai, Beijing, Hubei and Guangdong) had 1000--1500 cases; three provinces had 500- \<1000 cases; eleven provinces, 4 autonomous regions and 2 municipalities had 100--\<500 cases; 2 provinces had 50-- \< 100 cases; and 2 provinces had \<50 cases. Figure [S1](#MOESM1){ref-type="media"} presents the geographic distribution of cases in the 2001--2007 Chinese data meta-analysis: only 10 provinces, 4 autonomous regions and 2 municipalities reported TEVAR among type B AD patients, and the reported number of cases was only about one-tenth of that between 2008--2015; 2 municipalities and 1 province had 100--\<500 cases; 2 provinces and 1 autonomous region had 50--\<100 cases; 7 provinces and 3 autonomous regions had \<50 cases; and the remaining 12 provinces, 1 autonomous region and 2 municipalities had no studies reporting TEVAR. The proportion of cases treated by each specialist type was calculated (Fig. [S2A](#MOESM1){ref-type="media"}) and compared with 2001--2007 Chinese data (Fig. [S2B](#MOESM1){ref-type="media"}). Vascular surgery had the highest (\~40%) proportion of cases. When compared with 2001--2007 Chinese data, the proportion of cases in cardiology and cardiothoracic surgery both increased by over 5%, while that in interventional radiology decreased by 13%. Cases treated by general surgery were not reported in 2001--2007, and only accounted for a very small proportion (0.74%) in 2008--2015.Table 2Number of patients, studies, hospitals and departments by geographic area (Chinese mainland provinces/autonomous regions/municipalities).Provinces, autonomous regions and municipalitiesPatients (n)Studies (n)Hospitals (n)Departments (n)Patients per Department (n)Xinjiang35255570Beijing1281988160Guangxi22577732Anhui22475637Jiangsu75715151550Shan'xi41045582Qinghai5722229Sichuan24555549Hebei21555543Neimengu11054428Jiangxi32665654Chongqin16133354Shandong66813131351Zhejiang402333134Fujian18644447Heilongjiang14544436Gansu15754439Tianjin18433361Henan4651091047Guangdong105116202053Yunnan453444113Ningxia11822259Liaoning411444103Hunan633444158Hubei106613131382Guizhou61116Shanghai1428999159Jilin7244418Shanxi5622228Hainan1511115Total1187917517317667 Figure 2Geographical distribution of TEVAR cases in 30 administrative regions of mainland China (Jan. 2008--Oct. 2015). Number of cases was categorized into 5 levels (green: \<50, brown: 50--\<100, blue: 100--\<500, yellow: 500--\<1000, red: 1000--1500). This map is created using the "mapchart" online figure generator (<https://mapchart.net/>).

Procedural Data and In-Hospital Course {#Sec10}
--------------------------------------

Table [3](#Tab3){ref-type="table"} shows procedural data and in-hospital course. The majority of patients (71.8% among 5314) received general anesthesia. TEVAR was successful in 99.1% of 8885 patients. Regarding adjunctive techniques in TEVAR, covered left subclavian artery was used in 9.5%; debranch technique in 2.8% (among 8885 patients); and chimney technique in 6.1% among 783 patients. In-hospital major complications were reported in 1.7% of 6956 cases. The most critical in-hospital complications were related to retrograde dissection extension into the ascending aorta (0.4% of 6532 cases) and stent-graft related distal AD (0.1% of 6532 cases). In terms of neurologic complications, in-hospital paraplegia occurred in 0.4% of 1106 cases, and stroke occurred in 1.1% of 3695. Total in-hospital surgical conversion rate was 0.3% of 8885 cases. In-hospital adjunctive endovascular procedure was required in 0.3% of 8885 cases. One hundred and thirty-seven of 8316 cases died during the in-hospital period, yielding an overall in-hospital mortality rate of 1.6%. Type and proportion of in-hospital death causes are summarized in Fig. [3](#Fig3){ref-type="fig"}. Dissection rupture was the most common cause of death (32.1%). Among the 22 dissection rupture patients with known time of death, 36.4% died during the first postoperative day and 95.5% within postoperative week one. Figure [4](#Fig4){ref-type="fig"} shows the Kaplan-Meier curve for in-hospital death among patients with available data. Forty percent of deaths occurred during the first postoperative day, 50% within the first 3 postoperative days, and \~75% within the first postoperative week. Figure [S3](#MOESM1){ref-type="media"} depicts rates of procedure- and non--procedure-related deaths during hospitalization, which were statistically similar (0.8% vs. 0.6%, log-rank p = 0.765).Table 3Procedural data and in-hospital course.Data available (n)No. of events \[n(% ± SE)\]Anesthesia5314 General anesthesia3816 (71.8 ± 1.0%) Local anesthesia1283 (24.1 ± 2.9%) Lumber anesthesia22 (0.4 ± 0.0%) Epidural anesthesia174 (3.3 ± 0.0%)Procedure success88858809 (99.1 ± 0.8%) Covered left subclavian artery8885843 (9.5 ± 1.9%) Debranch8885248 (2.8 ± 0.9%) Chimney78348 (6.1 ± 0.5%)Major complications6956116 (1.7 ± 2.3%)Neurologic complications Stroke369542 (1.1 ± 2.4%) Paraplegia11064 (0.4 ± 0.0%)Stent graft induced new entry653232 (0.5 ± 0.0%) Retrograde type A AD653223 (0.4 ± 0.0%) Distal AD65329 (0.1 ± 0.0%)Surgical conversion888525 (0.3 ± 0.0%)Adjunctive endovascular procedures888525 (0.3 ± 0.0%)Mortality8316137 (1.6 ± 0.9%)Procedure related775465 (0.8 ± 0.0%)Non-procedure related775448 (0.6 ± 0.0%)AD: aortic dissection. Figure 3Types and proportions of in-hospital death causes. AD: aortic dissection, MOSF: multiple organ system failure, NA: not applicable. Figure 4Kaplan-Meier survival curve for in-hospital death. First day deaths accounted for about 40% (dot line), death within the first 3 postoperative days accounted for about 50% (long dash-dot-dot line), and deaths within the first postoperative week accounted for about 75% (short dash-dot line) of in-hospital deaths.

Follow-up data {#Sec11}
--------------

Patients were examined after one month from discharge using computed tomographic scanning. Major follow-up parameters are summarized in Table [4](#Tab4){ref-type="table"}. Follow-up information was available for 8387 patients. Time to follow-up (1--132 months) was available for 6883 patients. Late major complications were reported in 1.6% of 5942 cases. The most critical long-term complications were related to retrograde type A AD (0.3% of 6192 cases) and stent-graft related distal AD (0.5% of 6192 cases). Among 7938 patients with available data, late surgical conversions were performed in 0.2% cases, and adjunctive endovascular stent-graft procedures were performed in 1.1% cases. Type and proportion of long-term death causes are illustrated in Fig. [5](#Fig5){ref-type="fig"}. Dissection rupture accounted for most death (39.2%). Among the 17 dissection rupture patients with available information on death timing, 35.3% patients and 58.8% patients died within 6 and 12 months after discharge, respectively. Figure [6](#Fig6){ref-type="fig"} shows the Kaplan-Meier survival cure for long-term death among patients with available information. Death rate at one- and two- year follow up was about 50% and 75%, respectively; and 90% within 4 years of discharge. Figure [S4](#MOESM1){ref-type="media"} depicts procedure- and nonprocedure-related deaths during follow up, which were statistically similar (1.0% vs. 1.3%, P = 0.737).Table 4Follow up data.Data available (n)No. of events \[n(% ± SE)\]Follow up patients88858387 (94.4%)Duration of follow up (month)68831--132Major complications594297 (1.6%)Stent graft induced new entry619253 (0.8 ± 0.0%) Retrograde type A AD^\*^619221 (0.3 ± 0.0%) distal AD619232 (0.5 ± 0.0%)Surgical conversion793819 (0.2 ± 0.0%)Adjunctive endovascular procedures793887 (1.1 ± 0.0%)Mortality7001164 (2.3 ± 1.1%) Procedure related656964 (1.0 ± 0.0%) Non-procedure related656983 (1.3 ± 0.0%)^\*^AD: aortic dissection. Figure 5Types and proportions of long-term death causes. AD: aortic dissection, MOSF: multiple organ system failure, NA: not applicable. Figure 6Kaplan-Meier survival curve for long-term death. Death at one- and two- year follow-up accounted for about 50% (short dash-dot line) and 75% (dot line) of long-term deaths, respectively. 90% (long dash-dot-dot line) of deaths occurred within 4 years follow-up.

Discussion {#Sec12}
==========

The main findings in the present meta-analysis of 2008--2015 publications from mainland China on TEVAR for type B AD are a change in the geographic and specialty practice of TEVAR and apparently improved safety outcomes relative to prior time periods in mainland China and Western countries.

The distribution of medical resources and development of medical technique is unbalanced across different regions of mainland China. Beijing and Shanghai with the most advanced medical resources and techniques have attracted a large proportion of patients living in other regions of China. However, in 2008--2015, the difference in reported TEVAR numbers between Beijing/Shanghai and other locations decreased as compared to that of in 2001--2007^[@CR2]^, suggesting a rapidly increasing use of TEVAR during the past eight years in other regions of China, with the exception of no reports from Tibet, by 9- and 4-fold in the number of TEVAR and related studies, respectively.

In the past eight years, the shift in specialist type treating type B AD in mainland China from interventional radiologists to cardiologists and cardiothoracic surgeons while stable for vascular surgeons may reflect that more cardiologists and cardiothoracic surgeons are now capable of performing TEVAR; moreover, because interventional radiology is usually not the first specialty to which type B AD patients are referred, cardiologists, and cardiothoracic and vascular surgeons might become the main specialists treating type B AD in China.

The mean age of 53.9 years for type B AD patients in China is 7--9 years younger than those reported by Eggebrecht's^[@CR3]^, Hiratzka's^[@CR10]^ and Patel's^[@CR11]^ studies, suggesting an earlier onset of type B AD among Chinese compared with Caucasians in Europe and North America. Although published data suggest a lower prevalence of atherosclerosis among Chinese AD patients as compared to Caucasians, rates of postoperative neurological complications, namely stroke (p = 0.899) and paraplegia (p = 0.319) were statistically similar in this and the study by Eggbrecht *et al*.^[@CR3]^ (Table [5](#Tab5){ref-type="table"}). When compared with the study by Moulakakis *et al*. on a similar data collection time period (2006--2013), rates of stroke (p = 0.722) and paraplegia (p = 0.049) were statistically similar to those in our study for acute uncomplicated type B AD cases in the study by Moulakakis *et al*.^[@CR12]^. However, stroke (p = 0.001) and paraplegia (p = 0.007) rates were lower in our study as compared to the data from acute complicated type B AD in the study by Moulakakis *et al*.^[@CR12]^ (Table [6](#Tab6){ref-type="table"}).Table 5Results of comparison among the study by Eggbrecht *et al*., Chinese data (2001--2007) and Chinese data (2008--2015).Eggebrecht (1999--2004)China (2001--2007)China (2008--2015)P valueData available n\[%\]Data available (n\[%\])Data available (n\[%\])China (2008--2015) vs. China (2001--2007)China (2008--2015) vs. Eggebrecht (1999--2004)Number of publications3839152------Patients/center (median)10(3--127)16(3--179)30(5--578)------Procedure success551(90.5%)98.2 ± 0.5%1301(99.8%)99.2 ± 0.8%8885(74.8%)99.1 ± 0.8%0.2030.076Major complications449(73.7%)11.2 ± 1.4%1284(98.5%)3.4 ± 0.1%6956(58.6%)1.7 ± 2.3%\<0.001\<0.001Stroke518(85.1%)1.9 ± 0.6%1284(98.5%)0.2 ± 0.0%3695(31.1%)1.1 ± 2.4%\<0.0010.899Paraplegia609(100%)0.8 ± 0.4%1284(98.5%)01106(9.3%)0.4 ± 0.0%0.0030.319In-hospital mortality524(86.0%)5.3 ± 0.9%1304(100%)2.6 ± 0.1%8316(70.0%)1.6 ± 0.9%\<0.0010.001In-hospital retrograde type A dissection429(70.4%)1.9 ± 0.6%1301(99.8%)0.4 ± 0.0%6532(55.0%)0.4 ± 0.0%0.099\<0.001Long term mortality (Follow up month)609(100%)(19.5 ± 7.1)4.1 ± 0.9%1033(79.2%)(27.1 ± 17.5)1.5 ± 0.1%7001(58.9%)(1--132)2.3 ± 1.1%0.41\<0.001 Table 6Results of comparison among the study by Moulakakis *et al*. (2006--2013) and Chinese data (2008--2015).Moulakakis (2006--2013)Moulakakis (2006--2013)China (2008--2015)P valueData available (n\[%\]) Acute complicate type B ADData available (n\[%\]) Acute uncomplicated type B ADData available (n\[%\])China (2008--2015) vs. Moulakakis (2006--2013) acute complicated ADChina (2008--2015) vs. Moulakakis (2006--2013) acute uncomplicated ADNumber of publications3015152Stroke2246(88.7%)3.9 ± 3.8%1520(64.8%)1.6 ± 4.6%3695(31.1%)1.1 ± 2.4%0.0010.722Paraplegia2334(92.2%)3.0 ± 4.2%1654(70.5%)0.8 ± 1.5%1106(9.3%)0.4 ± 0.0%0.0070.049In-hospital mortality2531(100%)8.5 ± 7.0%2347(100%)4.8 ± 3.4%8316(70.0%)1.6 ± 0.9%\<0.0010.041Long term mortality (Follow up month)807(31.9%)(34.9 ± 14.5)23.4 ± 9.7%2101(89.5%)(44.0 ± 21.8)20.4 ± 14.4%7001(58.9%)(1--132)2.3 ± 1.1%\<0.001\<0.001

While the results of the present study indicate that TEVAR procedural success rate in China has remained stable over the past 15 years and comparable to that in Western countries, in-hospital mortality appeared to improve in mainland China from 2001--2007^[@CR2]^ to 2008--2015, becoming significantly lower to that in the study by Eggebrecht *et al*.^[@CR3]^. A similar trend was found when data from the present study were compared to those from the study by Moulakakis *et al*. (in acute complicated type B AD \[p \< 0.001\] and in acute uncomplicated type B AD \[p = 0.041\]) (Table [6](#Tab6){ref-type="table"}), and to the high in-hospital mortality (30% in complicated patients aged older than 70 years, and 10.1% in those younger than 70 years) from the International Registry of Acute Aortic Dissection (IRAD) study^[@CR11]^. The latter differences might be attributed to: continuous indication expansion and technical improvement for TEVAR during the past 8 years^[@CR6],[@CR13]^; and younger age of patients undergoing TEVAR in China than in Western countries, with reduced risk for postoperative cardiovascular and cerebrovascular adverse events or death.

Incidence of retrograde type A AD after TEVAR was significantly lower (approximately one fifth) both in 2008--2015 and 2001--2007 Chinese studies than in the study by Eggbrecht *et al*.^[@CR3]^, despite: (1) respective proportion of acute cases of 70%, 36% and 58.1%, which have been associated with a higher proportion of stent-graft induced new intimomedial tear due to very fragile aortic wall in acute stage of AD^[@CR14]--[@CR17]^; and (2) less conservative preference by Chinese surgeons during the past 8 years for 15% oversizing of stent-grafts. The lower incidence of post TEVAR retrograde type A AD tear might be explained by younger mean age in the Chinese patient population with less atherosclerotic burden in the landing zone allowing stronger resistance to stent-graft radial pressure, and increased use of domestic stent-grafts (over half of stent-grafts used in 2001--2007) with more recently optimized curve shaped design to better adapt to the anatomy of arch-descending aorta anatomy^[@CR8],[@CR18]^, and stent-graft struts designed to be in compliance with the upward convexity and forward convexity of arch-descending aorta to reduce intima trauma^[@CR19]--[@CR21]^.

Improvement in TEVAR diagnosis and timely intervention during the last 8 years might have been an important determinant in reducing nonprocedure-related mortality during hospitalization. Because of in-hospital death predominantly (75%) occurring during the first week after TEVAR and secondary to AD rupture, more attention should be paid during this period to signs and symptoms of impending AD rupture, such as persistent and aggressive chest pain, refractory hypertension, pleural effusion and proximal type I endoleak^[@CR22]^, in which case aorta CTA should be performed as soon as possible to ensure timely re-intervention.

Lower follow-up mortality in 2001--2007 and 2008--2015 Chinese data relative to that in the study by Eggebrecht *et al*.^[@CR3]^, and lower follow-up mortality in 2008--2015 Chinese data relative to that in the study by Moulakakis *et al*.^[@CR12]^ and the rather high 5-year mortality (16%) in the IRAD study^[@CR11]^, also might be attributed to the younger Chinese population with less comorbidity. Importance of surveillance extends to follow-up mortality with 33% and 60% of deaths occurring within the first 6 and 12 months of follow-up, respectively and 90% up to 4 years follow-up; therefore, continuous monitoring and disease management are most important and great attention should be paid to changes in AD morphology and signs of rapid growth of dissection and impending rupture (intermittent dull chest pain^[@CR23]^ or hoarseness of the voice^[@CR24]^) to ensure timely reintervention.

Although the present study provides a contemporary overview of use and effectiveness of TEVAR in treatment of type B AD in mainland China, including data by province, autonomous region and municipality, it has several limitations. Overall, the generalizability of the results of the present meta-analysis on prevalence of type-B dissection and major complication rates after TEVAR is limited by the high proportion of studies included that did not report pertinent data because of their research focus and design; information on several variables therefore was available for about 50% and in some cases less of total patients in the meta-analysis. More robust meta-analyses are warranted including future studies providing more comprehensive datasets. First, many studies did not clarify if type B AD was complicated or uncomplicated, which might influence post-TEVAR complication and mortality rate estimation thereby leading to misclassification bias when comparing to other meta-analyses. Second, most studies did not report stent-graft type, rendering unfeasible to accurately determine the effect of various types on TEVAR outcomes, especially endoleak and stent-graft-induced new entry. Third, because doctors from medical school affiliated, teaching and tertiary hospitals usually are more motivated to publish than those from non-tertiary hospitals; generalizability of study results might be limited. Fourth, beyond traditional hard endpoints, i.e., death and major complications, false lumen remodeling has been proposed as an important long-term outcome post TEVAR; however, few studies have reported on it. Fifth, most studies did not report patient comorbidities, such as cardiovascular and cerebrovascular diseases, which would bias postoperative morbidity and mortality estimation. Sixth, single center series included in this study might include highly selected patients that may introduce publication bias. Seventh, because follow up time in studies in the 2008--2015 Chinese dataset was expressed as a range of time and not a particular timepoint, overall median follow-up duration could not be calculated for comparisons with other published meta-analyses. Finally, the use of adjunctive techniques (such as debranch and chimney) in TEVAR has increased during the past 8 years, which may also increase the risk of procedure-related and postoperative morbidity; however, scarce information on their use did not allow to control for the related confounding effect.

In conclusion, the present study suggests that use and effectiveness of TEVAR for type B AD treatment in mainland China has improved over the years, achieving short- and long- term outcomes that are comparable and some possibly more favorable than those in Western countries. Further effort is required to establish more reliable and informative reporting protocols and systems at a national level to ensure generation of more comprehensive and generalizable evidence to guide future medical development in China.
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